Humira Will Overtake Remicade as the Crohn’s Disease Market Leader By 2012
Increased Uptake of Current Agents and Emergence of New Therapies Will Drive Robust Annual Market Growth, According to a New Report from Decision Resources
The new Pharmacor report entitled Crohn’s Disease finds that, owing to its convenient self-administration, Humira will continue its rise to leadership in the Crohn’s disease drug market as patients will favor Humira over Remicade, especially in the maintenance setting. Increased uptake of current agents and the emergence of new therapies will drive robust 8.8 percent annual growth in the Crohn’s disease market from 2007 to 2012 in
Among the emerging agents for Crohn’s disease, Cimzia will likely gain approval in
“Gastroenterologists we interviewed indicated that they are using biologic agents earlier in their treatment regimens for Crohn’s disease,” said
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 firstname.lastname@example.org email@example.com
SOURCE Decision Resources, Inc.